8-K filing — Cytosorbents Corp (CTSO)
Filed: 2026-09-23 AccNo: 0001104659-26-109814 Size: 286 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
CytoSorbents Q2 Adj. EPS $(0.07) Misses $(0.04) Estimate, Sales $9.633M Beat $9.346M Estimate
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CytoSorbents Regains Nasdaq Compliance
CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regained compliance with
Cytosorbents Announces 1-for-20 Reverse Stock Split, Effective September 8
Reverse Stock Split Previously Approved by Shareholders; Intended to Support Compliance with Nasdaq's $1.00 Minimum Bid Price RequirementExpected to Become Effective and Trade on Split-Adjusted Basis at the Market
CytoSorbents Says Real-World Matched Analysis Of 587 Urgent CABG Patients On Ticagrelor Showed 37% Relative Reduction In Severe Bleeding With CytoSorb; Plans New DrugSorb-ATR De Novo Submission In Early 2027